TET2 Mutation

CI-VAR-00002641Explore in graph →CIViC 157

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia5
TET2 Mutation	(prognostic)	Prognostic	B	Does Not Support N/A	4	accepted	EID415 In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death… (full text at CIViC) PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC	civic
TET2 Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID419 In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission. PMID 22430270 · Gaidzik et al., 2012 · Open in CIViC	civic
TET2 Mutation	(prognostic)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Diffuse Large B-Cell Lymphoma1
TET2 Mutation	(oncogenic)	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11992 This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC) PMID 28985567 · Reddy et al., 2017 · Open in CIViC	civic

Myelodysplastic Syndrome1
TET2 Mutation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID417 In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations. PMID 19666869 · Kosmider et al., 2009 · Open in CIViC	civic